The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis

Abstract Background Chimeric antigen receptor T (CAR T) cells immunotherapy is rapidly developed in treating cancers, especially relapsed or refractory B-cell malignancies. Methods To assess the efficacy and safety of CAR T therapy, we analyzed clinical trials from PUBMED and EMBASE. Results Results...

詳細記述

書誌詳細

出版年:	BMC Cancer
主要な著者:	Hui Zhou, Yuling Luo, Sha Zhu, Xi Wang, Yunuo Zhao, Xuejin Ou, Tao Zhang, Xuelei Ma
フォーマット:	論文
言語:	英語
出版事項:	BMC 2018-09-01
主題:	Chimeric antigen receptor T (CAR T) therapy Safety Efficacy Relapsed or refractory B-cell malignancies
オンライン･アクセス:	http://link.springer.com/article/10.1186/s12885-018-4817-4